Arcellx, Inc. is a biotechnology company focused on developing innovative therapies for patients with severe and life-threatening diseases, particularly in the field of cancer
The company's primary emphasis is on harnessing its proprietary technology to create targeted treatments that utilize the body's immune system to combat tumors effectively. Arcellx aims to address unmet medical needs by advancing its research and development programs, ultimately working towards improving patient outcomes and quality of life through cutting-edge therapeutic solutions.
Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.
